Literature DB >> 19931997

Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).

Feng Bai1, Fangyi Zhu, Michael Tagen, Laura Miller, Thandranese S Owens, Jeremy Mallari, Edward Derrick, Fan Zhang, Clinton F Stewart.   

Abstract

A sensitive and precise LC-ESI-MS/MS method for determination of nutlin-3a in murine plasma using ketoconazole as an internal standard was developed and validated. Plasma nutlin-3a samples were prepared by either a simple protein precipitation (PP) for the high concentration range (10-20,000ng/mL) or by liquid-liquid extraction (LLE) for the low concentration range (0.25-300ng/mL). Nutlin-3a and ketoconazole were separated on a modified C18 analytical column (4microm, 75mmx2mm) with an isocratic mobile phase (acetonitrile/5mM HCOONH(4)=70/30, v/v). The retention times of nutlin-3a and ketoconazole were 1.14 and 1.45min. Detection was achieved by a tandem MS system, monitoring m/z 582/99 and m/z 532/82 for nutlin-3a and ketoconazole, respectively. The PP method was linear in a range of 10-20,000ng/mL (R(2)>or=0.993) and the LLE method was linear in a range of 0.25-300ng/mL (R(2)>or=0.992). The mean recoveries for PP and LLE were 24% and 78%, respectively. Within-day and between-day precisions were <or=4.5% for PP and were <or=4.9% for LLE. Within-day and between-day accuracies (% error) ranged from 4.8 to -7.9 for PP, and from -0.2 to -8.4 for LLE. The two extraction methods produced equivalent results, allowing use of both within the same study. This method has been applied to the measurement of nutlin-3a concentrations in murine plasma samples obtained from a preclinical pharmacokinetic study. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931997      PMCID: PMC2814893          DOI: 10.1016/j.jpba.2009.10.016

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  18 in total

Review 1.  Ion suppression in mass spectrometry.

Authors:  Thomas M Annesley
Journal:  Clin Chem       Date:  2003-07       Impact factor: 8.327

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

Review 3.  MDM2 is a central node in the p53 pathway: 12 years and counting.

Authors:  Gareth L Bond; Wenwei Hu; Arnold J Levine
Journal:  Curr Cancer Drug Targets       Date:  2005-02       Impact factor: 3.428

4.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

5.  Stability assessment of ketoconazole in aqueous formulations.

Authors:  M Skiba; M Skiba-Lahiani; H Marchais; R Duclos; P Arnaud
Journal:  Int J Pharm       Date:  2000-03-30       Impact factor: 5.875

6.  Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.

Authors:  Simona Giglio; Francesca Mancini; Francesca Gentiletti; Giorgia Sparaco; Lara Felicioni; Fabio Barassi; Carla Martella; Andrea Prodosmo; Stefano Iacovelli; Fiamma Buttitta; Antonella Farsetti; Silvia Soddu; Antonio Marchetti; Ada Sacchi; Alfredo Pontecorvi; Fabiola Moretti
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

Review 7.  Functions of the MDM2 oncoprotein.

Authors:  D A Freedman; L Wu; A J Levine
Journal:  Cell Mol Life Sci       Date:  1999-01       Impact factor: 9.261

8.  Database of p53 gene somatic mutations in human tumors and cell lines.

Authors:  M Hollstein; K Rice; M S Greenblatt; T Soussi; R Fuchs; T Sørlie; E Hovig; B Smith-Sørensen; R Montesano; C C Harris
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

Review 9.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Authors:  Sanjeev Shangary; Shaomeng Wang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

10.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

View more
  4 in total

1.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

2.  Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

Authors:  Rachel C Brennan; Sara Federico; Cori Bradley; Jiakun Zhang; Jacqueline Flores-Otero; Matthew Wilson; Clinton Stewart; Fangyi Zhu; Kip Guy; Michael A Dyer
Journal:  Cancer Res       Date:  2011-04-22       Impact factor: 12.701

3.  MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.

Authors:  Fan Zhang; Stacy L Throm; Laura L Murley; Laura A Miller; D Steven Zatechka; R Kiplin Guy; Rachel Kennedy; Clinton F Stewart
Journal:  Biochem Pharmacol       Date:  2011-04-01       Impact factor: 5.858

4.  Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

Authors:  Fan Zhang; Michael Tagen; Stacy Throm; Jeremy Mallari; Laura Miller; R Kiplin Guy; Michael A Dyer; Richard T Williams; Martine F Roussel; Katie Nemeth; Fangyi Zhu; Jiakun Zhang; Min Lu; John C Panetta; Nidal Boulos; Clinton F Stewart
Journal:  Drug Metab Dispos       Date:  2010-10-14       Impact factor: 3.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.